Kinetics and crystal structure of adenylosuccinate lyase reveal its role in purine synthesis and potential in drug design against leishmaniasis.
One of several intriguing aspects of kinetoplastid biochemistry is the complete dependence on host purines and purine recycling due to the lack of a de novo purine biosynthesis pathway. Adenylosuccinate lyase (ASL, EC 4.3.2.2) is a key enzyme in the purine synthesis pathway responsible for the conversion of adenylosuccinate into adenosine monophosphate (AMP), representing a potential target for an effective drug design against leishmaniasis. Here, we report the in vitro kinetics studies and the crystal structure of the Leishmania major Friedlin adenylosuccinate lyase ( LmASL). Furthermore, we characterize allosteric communication networks within the protein. We also identified a phenylpiperazine derivative, itraconazole, as a promising candidate for selective interaction with the LmASL substrate-binding site by molecular docking and molecular dynamics simulations. Finally, we expand the current understanding on trypanosomatid ASL by demonstrating its requirement for the normal growth of Trypanosoma brucei procyclic form. Our data will substantiate future studies aimed at developing an effective and specific treatment against leishmaniasis.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: